Business
Corxel will use the fundraising proceeds to advance the oral GLP-1 therapy CX11 through mid-stage development in the U.S., as well as prepare for its Phase III studies.
FEATURED STORIES
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Seattle-based clinical-stage biopharmaceutical company Lumen Bioscience is teaming up with Novo Nordisk to explore research and development opportunities within obesity, among other metabolic disorders.
Both MannKind and United Therapeutics entered into a global and exclusive licensing and collaboration agreement to develop and commercialize Tyvaso DPI.
The research collaboration will see the development of bispecific antibodies and CAR-T cell products.
Each week more money pours into the biopharma world. Here’s a peek at who’s getting a taste of fresh funds this week.
This week, the German drug company announced that it is closing the doors to its ‘innovation hub’ in Mission Bay.
The Paris-based biotech will use the funds to create targeted immuno-oncology treatments for a broader range of patients with its next-generation CAR-T and epigenetics platform.
The study drug is a once-daily, two-week therapy developed by Sage Therapeutics and Biogen for major depressive disorder (MDD) and postpartum depression (PPD).
Umoja Biopharma, Alentis Therapeutics, RayzeBio and Camp4 Therapeutics are ramping up on series funds.
The new division would benefit from Hahn’s experience and help steer the company’s Preemptive Medicine and Health Security initiative.